Headquartered in South San Francisco, CA·Fiscal year ends December·NASDAQ: ALXO·alxoncology.com
About ALX Oncology Holdings
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company developing cancer therapies and does not yet generate revenue.
Its lead candidate, evorpacept, is a CD47 checkpoint inhibitor designed to activate the innate immune system while reducing the toxicities of earlier CD47-blocking approaches. Key details:
- It has been studied in more than 750 patients.
- It is being developed mainly in combination with anti-cancer antibodies in breast, gastric and colon cancers.
- The FDA granted it Fast Track designation, and both the FDA and European Commission granted Orphan Drug Designation, for second-line HER2-positive gastric/GEJ carcinoma.
- Randomized Phase 2 ASPEN-06 data were published in Nature Medicine and support CD47 as a potential predictive biomarker.
- The ongoing Phase 2 ASPEN-09-Breast trial tests evorpacept with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer.
The second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate built on the company's proprietary topoisomerase I inhibitor payload and linker platform. It is in a Phase 1 dose-escalation trial in patients with EGFR-expressing solid tumors.
The company funds operations through equity and debt financing and reports a cash runway into the first half of 2028. Updated